Repurposing the Oncolytic Virus VSV∆51M as a COVID-19 Vaccine

Frontiers in Bioengineering & Biotechnology

This article presents how the VSV∆51M-RBD vaccine exhibited safety, immunogenicity, and the potential to serve as a safe and effective alternative or complementary platform to current COVID-19 vaccines.

Journal Article